Immuneering Corporation
IMRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $86 | $0 | $0 | $175 |
| Gross Profit | -$86 | $0 | $0 | -$175 |
| % Margin | – | – | – | – |
| R&D Expenses | $10,808 | $10,454 | $11,472 | $14,796 |
| G&A Expenses | $0 | $4,296 | $4,006 | $0 |
| SG&A Expenses | $4,487 | $4,296 | $4,006 | $3,587 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $8 | $7 | $0 |
| Operating Expenses | $15,295 | $14,758 | $15,485 | $18,384 |
| Operating Income | -$15,381 | -$14,758 | -$15,485 | -$18,558 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $416 | $324 | $438 | $507 |
| Pre-Tax Income | -$14,965 | -$14,433 | -$15,046 | -$18,051 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14,965 | -$14,434 | -$15,046 | -$18,051 |
| % Margin | – | – | – | – |
| EPS | -0.38 | -0.4 | -0.42 | -0.58 |
| % Growth | 5% | 4.8% | 27.6% | – |
| EPS Diluted | -0.38 | -0.4 | -0.42 | -0.58 |
| Weighted Avg Shares Out | 39,670 | 35,986 | 35,530 | 31,050 |
| Weighted Avg Shares Out Dil | 39,670 | 35,986 | 35,530 | 31,050 |
| Supplemental Information | – | – | – | – |
| Interest Income | $415,831 | $324 | $439 | $415 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $86 | $92 | $93 | $175 |
| EBITDA | -$14,879 | -$14,666 | -$15,392 | -$17,877 |
| % Margin | – | – | – | – |